ut-231b
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2003 (NCT00069511)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Hepatitis C virusINHIBITOR
Hepatitis C virus inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCOCCCCCCN1C[C@H](O)[C@@H](O)[C@@H](O)[C@H]1C.O=C(O)[C@H](O)[C@@H](O)C(=O)O- Mol. weight
- 425.48 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4300049 ↗
- ChEMBLCHEMBL4297332 ↗
Also known as
- ut-231b
- ut-231b
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00069511 | Phase 2 | Jul 1, 2003 | United Therapeutics |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| United Therapeutics | For profit | 1 | 1 | 1 | 2003 |
1 organizations
Page 1 / 1